Vector, Per Se (e.g., Plasmid, Hybrid Plasmid, Cosmid, Viral Vector, Bacteriophage Vector, Etc.) Bacteriophage Vector, Etc.) Patents (Class 435/320.1)
  • Polypeptide for hydrolytic cleavage of zearalenone and/or zearalenone derivatives, isolated polynucleotide thereof as well as a polypeptide containing an additive, use of same as well as a process
    Patent number: 10076125
    Abstract: The invention relates to a polypeptide for the hydrolytic cleavage of zearalenone and/or at least one zearalenone derivative, said polypeptide being a hydrolase having an amino acid sequence selected from the group consisting of SEQ ID NO: 1-15 or a functional variant thereof, wherein the sequence of the functional variant is at least 40% identical to at least one of the amino acid sequences. The invention also relates to: an additive containing the polypeptide; an isolated polynucleotide that encodes the polypeptide; and a method for the hydrolytic cleavage of zearalenone and/or of at least one zearalenone derivative using the polypeptide.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: September 18, 2018
    Assignee: ERBER AKTIENGESELLSCHAFT
    Inventors: Sebastian Fruhauf, Michaela Thamhesl, Martin Pfeffer, Dieter Moll, Gerd Schatzmayr, Eva Maria Binder
  • Universal donor system for gene targeting
    Patent number: 10077449
    Abstract: A universal donor polynucleotide is described that can be inserted at targeted locations in plant genomes to facilitate rapid and high throughput integration of a donor molecule within a specific genomic location.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: September 18, 2018
    Assignee: Dow AgroSciences LLC
    Inventors: Lakshmi Sastry-Dent, Steven L. Evans, Ryan C. Blue, Zehui Cao
  • Composition for treating HBV infection
    Patent number: 10076570
    Abstract: The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.
    Type: Grant
    Filed: March 17, 2012
    Date of Patent: September 18, 2018
    Assignee: Transgene S.A.
    Inventors: Perrine Martin, Geneviève Inchauspe, Nathalie Silvestre, Doris Schmitt, Alexei Evlachev
  • Use of centrifugation-aided infection to increase virus titer
    Patent number: 10066213
    Abstract: The invention relates to a process for increasing the observed titer of a virus stock for the purpose of increasing the calculated log reduction (LRV) in virus clearance studies. A tissue culture or assay plate is seeded with an indicator cell line and titrated with a virus stock followed, by a centrifugation step for about 5 minutes to about 24 hours at a g-force ranging from about 50×g to about 2400×g, and at a temperature from about 4° C. to about 39° C. The resulting calculated virus titer after undergoing the centrifugation step is 10-fold higher than the virus titer would be if determined in the absence of the centrifuging step.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: September 4, 2018
    Assignee: EMD Millipore Corporation
    Inventors: Damon Asher, Anne Leahy
  • Small interfering RNAs with target-specific seed sequences
    Patent number: 10066236
    Abstract: Disclosed are methods for design and synthesis of siRNA libraries, siRNA libraries produced thereby, siRNA molecules, and uses thereof.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: September 4, 2018
    Assignee: Syngenta Participations AG
    Inventors: Xiang Huang, Thomas Z. McNeill, Micheal Schweiner
  • Plant regulatory elements from a ubiquitin gene from bouteloua gracilis
    Patent number: 10059954
    Abstract: The invention provides novel recombinant DNA molecules and constructs useful for modulating gene expression in plants, plant cells, seeds, and progeny plants. Plant regulatory elements comprising sequences from a ubiquitin gene from Bouteloua gracilis, as well as variants and fragments thereof having gene-regulatory activity, are provided. The invention also provides transgenic plants, plant cells, plant parts, seeds, and progeny plants comprising the recombinant DNA molecules of the invention, along with methods of their use.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: August 28, 2018
    Assignee: Monsanto Technology LLC
    Inventor: Stanislaw Flasinski
  • Pharmaceutical compositions for prevention or treatment of neurodegenerative diseases
    Patent number: 10059748
    Abstract: The present invention relates to methods and compositions for the prevention or treatment of neurodegenerative diseases.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: August 28, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ PAUL SABATIER TOULOUSE III, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ PIERRE ET MARIE CURIE (PARIS 6), ICM (INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE)
    Inventors: Daniel Dunia, Marion Szelechowski, Alexandre Betourne, Stephane Hunot
  • Maize hybrid X18K365
    Patent number: 10051809
    Abstract: A novel maize variety designated X18K365 and seed, plants and plant parts thereof are produced by crossing inbred maize varieties. Methods for producing a maize plant by crossing hybrid maize variety X18K365 with another maize plant are disclosed. Methods for producing a maize plant containing in its genetic material one or more traits introgressed into X18K365 through backcross conversion and/or transformation, and to the maize seed, plant and plant part produced thereby. This invention relates to the maize variety X18K365, the seed, the plant produced from the seed, and variants, mutants, and minor modifications of maize variety X18K365. This invention further relates to methods for producing maize varieties derived from maize variety X18K365.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: August 21, 2018
    Assignee: PIONEER HI-BRED INTERNATIONAL, INC.
    Inventors: Joseph D Anderson, Terry R Colbert, Mark Jacob Gadlage
  • Compositions and methods for inhibiting HMGB1 activation of melanocytes
    Patent number: 10054582
    Abstract: A method of identifying a test agent as a skin tone agent. The method includes determining the level of high-mobility group protein B1 (HMGB1), messenger RNA associated with the expression and/or regulation of HMGB1 (HMGB1 mRNA), and/or micro-RNA associated with the expression and/or regulation of HMGB1 (HMGB1 miRNA) present in the test sample, and identifying the test agent as a skin tone agent when there is no increase in HMGB1 level, a downregulation in transcription of HMGB1 mRNA, and/or an upregulation of HMGB1 miRNA. The method also includes identifying a test agent as a skin tone agent when the test agent inhibits or prevents an increase in melanocyte dendricity and/or body size caused by HMGB1.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: August 21, 2018
    Assignee: The Procter & Gamble Company
    Inventors: Leo Timothy Laughlin, II, Tomohiro Hakozaki, Wenzhu Zhao
  • nonhost resistance gene(s) and use thereof to engineer disease resistant plants
    Patent number: 10045499
    Abstract: The present invention relates to a method of increasing resistance against plant pathogens, particularly Phytophthora and Fusarium virguliforme in transgenic plants and/or plant cells, through the use of non host resistance nucleic acid molecules isolated from Arabidopsis. In these plants, at least one nonhost Arabidopsis resistance protein is introduced in comparison to the wild-type plants to confer resistance to plant pathogens. The invention relates to transgenic plants and/or plant cells having an increased resistance against plant pathogens particularly Phytophthora and Fusarium virguliforme to expression vectors, transformed plants and plant cells as well as the use of such plants in a plant breeding program.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: August 14, 2018
    Assignee: Iowa State University Research Foundation, Inc.
    Inventors: Madan K. Bhattacharyya, Rishi Sumit, Binod B. Sahu
  • Methods and compositions for modulating PD1
    Patent number: 10046028
    Abstract: Disclosed herein are methods and compositions for modulating expression of a PD1 gene.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: August 14, 2018
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Philip D. Gregory, Michael C. Holmes, Matthew C. Mendel, Xiangdong Meng, David Paschon, Andreas Reik, Fyodor Urnov
  • Feruloyl-CoA:monolignol transferase
    Patent number: 10047113
    Abstract: The invention relates to nucleic acids encoding a feruloyl-CoA:monolignol transferase and the feruloyl-CoA:monolignol transferase enzyme that enables incorporation of monolignol ferulates, for example, including p-coumaryl ferulate, coniferyl ferulate, and sinapyl ferulate, into the lignin of plants.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: August 14, 2018
    Assignees: Board of Trustees of Michigan State University, The University of British Columbia, Wisconsin Alumni Research Foundation
    Inventors: Curtis Wilkerson, John Ralph, Saunia Withers, Shawn D. Mansfield
  • Compositions and methods for expressing genes in algae
    Patent number: 10041079
    Abstract: The present application provides novel regulatory elements including promoter sequences from microorganisms. The application further discloses DNA constructs containing these novel regulatory elements, and recombinant microorganisms comprising these regulatory elements. Methods of modifying, producing, and using the regulatory elements are also disclosed. The regulatory elements and transformation methods disclosed herein are particularly suited for use in Parachlorella and other microalgae.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: August 7, 2018
    Assignee: Synthetic Genomics, Inc.
    Inventors: Eric R. Moellering, Amanda R. Edwards, Nicholas Bauman
  • Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
    Patent number: 10041072
    Abstract: In one aspect, the invention provides methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector (FIG. 1A). Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell. In a further aspect, the invention provides methods for producing siRNA encoding lentivirus where the siRNA activity may interfere with the lentiviral life cycle. In yet a further aspect, the invention provides methods for expression of a small RNA molecule within a cell, such as an siRNA capable of downregulating CCR5, wherein expression of the small RNA molecule is relatively non-cytotoxic to the cell. The invention also includes small RNA molecules, such as an siRNA capable of downregulating CCR5, that are relatively non-cytotoxic to cells.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: August 7, 2018
    Assignee: California Institute of Technology
    Inventors: Carlos Lois-Caballe, David Baltimore, Xiao-Feng Qin, Irvin S. Y. Chen, Dong Sung An
  • Plant type related protein, and coding gene and application thereof
    Patent number: 10041085
    Abstract: A plant type related protein, and a coding gene and an application thereof are provided. The protein is: (a) a protein consisting of the amino acid sequence of SEQ ID NO: 1; (b) a SEQ ID NO: 1-derived protein having substitution, deletion, and/or addition of an amino acid residue on the sequence of SEQ ID NO: 1, and related to the plant type and/or inactivation of a plant brassinolide type, or (c) a protein having more than 80% homology to the sequence of SEQ ID NO: 1 and related to a plant type and inactivation of a plant brassinolide type. The protein and its coding gene have very important value in improving crop production, improving the visual enjoyability of a green plant, implementing simple cultivation of a plant and improving the breeding efficiency, and has a broad prospective in genetic improvement of a plant, new variety cultivation and an application.
    Type: Grant
    Filed: April 9, 2013
    Date of Patent: August 7, 2018
    Assignee: Cotton Research Institute, Chinese Academy of Agricultural Sciences
    Inventors: Fuguang Li, Zuoren Yang, Chaojun Zhang, Yufen Wang, Zhixia Wu, Chuanliang Liu, Xueyan Zhang, Ye Wang, Fenglian Li, Qianhua Wang, Wenqiang Qin, Depei Kong
  • Plants having increased tolerance to herbicides
    Patent number: 10041087
    Abstract: The present invention refers to a method for controlling undesired vegetation at a plant cultivation site, the method comprising the steps of providing, at said site, a plant that comprises at least one nucleic acid comprising a nucleotide sequence encoding a wild-type or a mutated protoporphyrinogen oxidase (PPO) which is resistant or tolerant to a benzoxazinone-derivative herbicide by applying to said site an effective amount of said herbicide. The invention further refers to plants comprising wild-type or mutated PPO enzymes, and methods of obtaining such plants.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: August 7, 2018
    Assignee: BASF AGRO B.V.
    Inventors: Raphael Aponte, Stefan Tresch, Matthias Witschel, Jens Lerchl, Jill Marie Paulik, Chad Brommer
  • Group B adenovirus modified in the E4orf4 region
    Patent number: 10034905
    Abstract: The present disclosure relates to a type B adenovirus wherein E4orf4 is deleted or non-functional and generally having a DNA sequence in the E3 region, in particular viruses of formula (I), compositions containing the virus, for example pharmaceutical formulations of the virus, processes for making the viruses and the compositions and use of any one of the same in treatment, particularly in the treatment of cancer, such as colorectal cancer and ovarian cancer. 5?ITR-B1-BA-B2-BX-BB-BT-B3-3?ITR??(I).
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: July 31, 2018
    Assignee: PSIOXUS THERAPEUTICS LIMITED
    Inventors: Leonard Charles William Seymour, Alice Claire Noel Brown, Brian Robert Champion
  • Risk stratification in influenza
    Patent number: 10036075
    Abstract: The present invention relates to methods for the identification of clinical risk in patients having, or suspected of having, influenza. The invention also relates to methods for distinguishing between patients having influenza or viral pneumonia from patients having a symptomatically similar condition. The methods of the invention comprise determination of the level of expression of interferon alpha inducible protein 27 (IF127) in a biological sample from a patient having, or suspected of having, influenza. Kits comprising suitable components for the performance of the methods are also provided by the invention. The invention allows stratification of patients into groups defining clinical risk, for example groups based on the severity of risk to the long-term health of the subject.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: July 31, 2018
    Assignee: Nepean Blue Mountains Local Health District
    Inventors: Anthony McLean, Benjamin Tang, Grant Peter Parnell, Maryam Shojaei
  • Maize inbred PH2WSG1
    Patent number: 10021846
    Abstract: A novel maize variety designated PH2WSG1 and seed, plants and plant parts thereof are provided. Methods for producing a maize plant comprise crossing maize variety PH2WSG1 with another maize plant are provided. Methods for producing a maize plant containing in its genetic material one or more traits introgressed into PH2WSG1 through backcross conversion and/or transformation, and to the maize seed, plant and plant part produced thereby are provided. Hybrid maize seed, plants or plant parts are produced by crossing the variety PH2WSG1 or a locus conversion of PH2WSG1 with another maize variety.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: July 17, 2018
    Assignee: PIONEER HI-BRED INTERNATIONAL, INC.
    Inventor: Mario Rosario Carlone, Jr.
  • Fungal resistant plants expressing HCP5
    Patent number: 10023875
    Abstract: The present invention relates to a method of increasing resistance against fungal pathogens of the order Pucciniales, preferably the family Phacopsoraceae, in plants and/or plant cells. This is achieved by increasing the expression of an HCP5 protein or fragment thereof in a plant, plant part and/or plant cell in comparison to wild type plants, wild type plant parts and/or wild type plant cells. Furthermore, the invention relates to transgenic plants, plant parts, and/or plant cells having an increased resistance against fungal pathogens, in particular, pathogens of the order Pucciniales, preferably the family Phacopsoraceae, and to recombinant expression vectors comprising a sequence that is identical or homologous to a sequence encoding an HCP5 protein.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: July 17, 2018
    Assignee: BASF PLANT SCIENCE COMPANY GMBH
    Inventors: Holger Schultheiss, Ralf Flachmann
  • Identification and characterization of a peptide affinity reagent for the detection of noroviruses in clinical samples
    Patent number: 10024856
    Abstract: Embodiments of the disclosure include methods and/or compositions for the detection of viral infection, including at least Norovirus infection. In particular embodiments, there are methods and/or compositions employing particular peptides and/or phage useful for detecting Norovirus in a sample. The sample may be from an environment or from an individual. The individual may be a mammal, including a human, cow, horse, dog, cat, pig, and so forth. Certain exemplary peptides and phage that express the peptides are identified as useful for binding to Norovirus. Such peptides and phage are provided to one or more samples in order to identify whether or not Norovirus is present in the sample.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: July 17, 2018
    Assignee: Baylor College of Medicine
    Inventors: Timothy Gerald Palzkill, Mary K. Estes, Robert Legare Atmar, Jennifer Dawn Rogers, Nadim Jose Ajami
  • Long-acting recombinant human follicle-stimulating hormone-Fc fusion protein
    Patent number: 10023624
    Abstract: Recombinant Fc fusion proteins of human follicle-stimulating hormone (hFSH) with in vivo biological activities comparable to those of human follicle-stimulating hormone are disclosed. A recombinant hFSH-Fc fusion protein comprises ? subunit of hFSH (hFSH ?), CTP, ? subunit of hFSH (hFSH ?), a flexible peptide linker, and human IgG2 Fc variant (vIgG2Fc). A method is also disclosed to make such fusion proteins at good expression levels. These recombinant hFSH-Fc fusion proteins of the present disclosure exhibit sufficient biological activities and prolonged plasma half-lives, leading to improved pharmacokinetics and pharmacodynamics. Thus, a lower dosage may be used and/or better or different therapeutic efficacies with less side effects may be achieved. A method for the application of the recombinant hFSH-Fc fusion proteins in the treatment and/or prevention of human infertility is also disclosed.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: July 17, 2018
    Assignee: UnicoHealth Co. Ltd.
    Inventors: Yongmin Hou, Qiang Li, Maobo Wu, Sha Liao, Yujie Zhang, Zhenqi Xu
  • Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
    Patent number: 10017753
    Abstract: The present invention provides isolated polypeptides having cellulolytic enhancing activity and polynucleotides encoding the polypeptides. The invention also provides nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: July 10, 2018
    Assignee: Novozymes, Inc.
    Inventors: Yu Zhang, Junxin Duan, Lan Tang
  • Therapeutic compositions and methods for antibody and Fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
    Patent number: 10005820
    Abstract: The present application relates to the use of bacterial minicells as targeted delivery agents in vivo and in vitro. Described herein are genetically engineered eubacterial minicells designed to preferentially target and deliver therapeutically relevant agents using a minicell surface coupling molecule capable of binding and displaying antibodies or other Fc-containing targeting moiety fusions and conjugates.
    Type: Grant
    Filed: February 15, 2012
    Date of Patent: June 26, 2018
    Assignee: VAXIION THERAPEUTICS, LLC
    Inventors: Matthew J. Giacalone, Michael J. Newman
  • Means and methods for altering the lignin pathway in plants
    Patent number: 10006041
    Abstract: The disclosure generally relates to the field of molecular biology, specifically the field of agricultural biology. In particular, the disclosure relates to means and methods for modifying the lignin flu and composition in plants. In particular, the disclosure provides chimeric genes comprising transaldolase sequences, which can be used in the context of this disclosure.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: June 26, 2018
    Assignees: VIB VZW, UNIVERSITEIT GENT
    Inventors: Wout Boerjan, Ruben Vanholme, Lisa Sundin
  • Method of rapidly producing improved vaccines for animals
    Patent number: 10004797
    Abstract: A method of quickly producing a vaccine for a biotype of pathogenic microorganism is described, where a nucleic acid molecule or fragment thereof is obtained from a biological sample from an animal exposed to the microorganism, a protective molecule is prepared based on the nucleic acid molecule of interest or fragment thereof, and administered to an animal which has been or is as risk of being exposed to the microorganism. A protective response to the biotype of the microorganism is obtained in the animal.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: June 26, 2018
    Assignee: Harrisvaccines, Inc.
    Inventors: Delbert Linn Harris, Matthew Erdman, Kurt Iver Kamrud, Jonathan Fowler Smith, John Dustin Loy, Lyric Colleen Bartholomay, Ed Scura
  • Antisense composition and method for treating muscle atrophy
    Patent number: 10006031
    Abstract: A method and compound for treating skeletal muscle mass deficiency in a human subject are disclosed. The composition is an oligomer of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5? exocyclic carbon of an adjacent subunit, contains between 10-40 nucleotide bases, has a base sequence effective to hybridize to an expression-sensitive region of processed or preprocessed human myostatin RNA transcript, identified, in its processed form, by SEQ ID NO: 6, and is capable of uptake by target muscle cells in the subject. In practicing the method, the compound is administered in an amount and at a dosage schedule to produce an overall reduction in the level of serum myostatin measured in the patient, and preferably to bring the myostatin level within the a range determined for normal, healthy individuals.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: June 26, 2018
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Patrick L. Iversen, Dwight D. Weller, Alan P. Timmins
  • Hypoxia Inducible Factor (HIF) Activity Reporter Cell Line
    Patent number: 9995730
    Abstract: The present invention relates to the construction of a new hypoxia inducible factor (HIF) responsive reporter gene construct, the genetic constructs and vectors containing the same. Further, the present invention relates to a stable cell line comprising the HIF responsive reporter construct, as well as methods and uses of the inventive constructs and cell lines to identify modulators of HIF activity.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: June 12, 2018
    Assignee: UNIVERSITI PUTRA MALAYSIA
    Inventors: Norazizah Shafee, Eric J. Stanbridge, Khatijah Yusoff, Sien-Yei Liew
  • Method of targeting gene delivery using viral vectors
    Patent number: 9994867
    Abstract: Methods and compositions are provided for delivering a polynucleotide encoding a gene of interest to a target cell using a virus. The virus envelope comprises a cell-specific binding determinant that recognizes and binds to a component on the target cell surface, leading to endocytosis of the virus. A separate fusogenic molecule is also present on the envelope and facilitates delivery of the polynucleotide across the membrane and into the cytosol of the target cell. The methods and related compositions can be used for treating patients having suffering from a wide range of conditions, including infection, such as HIV; cancers, such as non-Hodgkin's lymphoma and breast cancer; and hematological disorders, such as severe combined immunodeficiency.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: June 12, 2018
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: David Baltimore, Pin Wang, Lili Yang
  • EBV antigen specific T-cell receptor and use thereof
    Patent number: 9993526
    Abstract: The present invention relates to an EBV antigen specific T-cell receptor and the use thereof. Specifically, the present invention provides T cells specific for LMP1 of EBV using a T-cell receptor which is highly specific for specific epitopes derived from an EBV antigen, LMP1. In addition, the EBV antigen specific T-cell can be used in the prevention or treatment of EBV-associated diseases.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: June 12, 2018
    Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Tai Gyu Kim, Hyun Il Cho
  • Oncolytic adenoviruses armed with heterologous genes
    Patent number: 9987314
    Abstract: The present disclosure relates to a group B adenovirus comprising a sequence of formula (I): 5?ITR-B1-BAB2-BX-BB-BY-B3-3?ITR wherein: B1 is bond or comprises: E1A, E1B or E1AE1B; BA comprises: E2B-L1-L2-L3-E2A-L4; B2 is a bond or comprises: E3; BX is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; BB comprises L5; BY is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; B3 is a bond or comprises: E4; wherein at least one of BX or BY is not a bond, pharmaceutical compositions comprising the same and use of the viruses and compositions in treatment, particularly in the treatment of cancer. The disclosure also extends to plasmids and processes employed to prepare the said viruses.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: June 5, 2018
    Assignee: Psioxus Therapeutics Limited
    Inventors: Brian Robert Champion, Alice Claire Noel Brown, Kerry David Fisher, Tamara Nicolson
  • Conserved HBV and HCV sequences useful for gene silencing
    Patent number: 9982263
    Abstract: Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: May 29, 2018
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Catherine J Pachuk, Chandrasekhar Satishchandran, Vincent R. Zurawski, Liat Mintz
  • Temporal regulation of gene expression by microRNAs
    Patent number: 9976152
    Abstract: This invention provides molecular constructs and methods for the temporally specific control of gene expression in plants or in plant pests or pathogens. More specifically, this invention provides plant miRNA genes having novel circadian expression patterns that are useful for designing recombinant DNA constructs for temporally specific expression of at least one gene. Also provided are non-natural transgenic plant cells, plants, and seeds containing in their genome a recombinant DNA construct of this invention.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: May 22, 2018
    Assignee: MONSANTO TECHNOLOGY LLC
    Inventors: Edwards M. Allen, Sara E. Heisel, Sergey Ivashuta, Elysia K. Krieger, Jennifer Lutke, Robert J. Meister, Yuanji Zhang
  • Recombinant DNA for gene suppression
    Patent number: 9976139
    Abstract: Anti-sense-oriented RNA gene suppression agents in the form of a loop of anti-sense-oriented RNA is produced in cells of transgenic organisms, e.g. plants, by transcription from a recombinant DNA construct which comprises in 5? to 3? order a promoter element operably linked to an anti-sense-oriented DNA element and a complementary DNA element.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: May 22, 2018
    Assignee: Monsanto Technology LLC
    Inventors: Shihshieh Huang, Thomas M. Malvar, Michael H. Luethy
  • Group of glycosyltransferases and use thereof
    Patent number: 9976167
    Abstract: Provided are the use of glycosyltransferases gGT25, gGT13, gGT30, gGT25-1, gGT25-3, gGT25-5, gGT29, gGT29-3, gGT29-4, gGT29-5, gGT29-6, gGT29-7, 3GT1, 3GT2, 3GT3, 3GT4 and derived polypeptides therefrom in the catalyzed glycosylation of terpenoid compounds and the synthesis of new saponins, wherein the glycosyltransferases can specifically and efficiently catalyze tetracyclic triterpenoid compound substrates at positions C-20 and/or C-6 and/or C-3 during hydroxyl glycosylation, and/or transfer the glycosyl from a glycosyl donor to the first glycosyl of the tetracyclic triterpenoid compounds at position C-3, so as to extend the sugar chain. The glycosyltransferases can also be used for constructing man-made synthetic rare ginsenosides and a variety of new ginsenosides and derivatives thereof.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: May 22, 2018
    Assignee: Shanghai Institutes For Biological Sciences, Chinese Academy Of Sciences
    Inventors: Zhihua Zhou, Xing Yan, Yun Fan, Pingping Wang, Yongjun Wei, Wei Wei, Jun Zhang
  • Transgenic plants
    Patent number: 9976156
    Abstract: The invention relates to methods for increasing total lysine content in plants and plant products and related uses.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: May 22, 2018
    Assignee: Consejo Superior De Investigaciones Cientificas (CSIC)
    Inventor: Francisco Barro Losada
  • Pesticidal toxin active against coleopteran and/or hemipteran insects
    Patent number: 9974302
    Abstract: The present invention provides novel insecticidal proteins active against a Coleopteran and/or Hemipteran species pest, which include, but are not limited to, TIC3131, TIC3400 and TIC3407 proteins. The present invention also provides a DNA construct comprising operably linked to a heterologous promoter a polynucleotide that encodes the novel insecticidal protein or an insecticidal fragment thereof. The present invention further provides transgenic plants/plant cells/plant parts expressing the insecticidal proteins, methods for detecting the presence of the polynucleotide or the protein in a biological sample, and methods of controlling a Coleopteran and/or Hemipteran species pest using the insecticidal proteins.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: May 22, 2018
    Assignee: Monsanto Technology LLC
    Inventors: Heather M. Anderson, David J. Bowen, Catherine A. Chay, Stanislaw Flasinski, Uma R. Kesanapalli, Jason S. Milligan, Rachael N. Slightom, Yong Yin
  • Synthetic conjugate of CpG DNA and T-help/CTL peptide
    Patent number: 9974854
    Abstract: Highly effective vaccine compositions are constructed according to the methods of this invention. The methods are amenable to use with any peptidic antigen sequence and involve covalent attachment of an immunostimulatory nucleotide sequence to an antigenic peptide sequence. Preferred antigenic peptides are fusion peptides made up of one or more CTL epitope peptides in sequence fused to a T helper peptide.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: May 22, 2018
    Assignee: City of Hope
    Inventor: Don J. Diamond
  • IDNA vaccines and methods for using the same
    Patent number: 9968672
    Abstract: Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: May 15, 2018
    Assignee: MEDIGEN, INC.
    Inventors: Peter Pushko, Igor Lukashevich
  • Soybean cultivar CL1563225
    Patent number: 9961865
    Abstract: The present invention is in the field of soybean variety CL1563225 breeding and development. The present invention particularly relates to the soybean variety CL1563225 and its seed, cells, germplasm, plant parts, and progeny, and methods of using CL1563225 in a breeding program.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: May 8, 2018
    Assignee: Syngenta Participations AG
    Inventors: David Scott Lee, Brian Erdahl
  • DNMT inhibitors
    Patent number: 9963705
    Abstract: RNA molecules inhibiting a DNMT and methods and compositions incorporating or generating the RNA molecules are described.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: May 8, 2018
    Assignee: New England Biolabs, Inc.
    Inventors: Sriharsa Pradhan, Pierre O. Esteve, Guoqiang Zhang
  • Soybean cultivar CL1561726
    Patent number: 9961864
    Abstract: The present invention is in the field of soybean variety CL1561726 breeding and development. The present invention particularly relates to the soybean variety CL1561726 and its seed, cells, germplasm, plant parts, and progeny, and methods of using CL1561726 in a breeding program.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: May 8, 2018
    Assignee: Syngenta Participations AG
    Inventors: David Scott Lee, Brian Erdahl
  • Biocatalytic process for preparing eslicarbazepine and analogs thereof
    Patent number: 9963683
    Abstract: The present disclosure relates to biocatalysts and its uses for the efficient preparation of eslicarbazepine, eslicarbazepine acetate, and analogs thereof.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: May 8, 2018
    Assignee: Codexis, Inc.
    Inventors: Anupam Gohel, Derek J. Smith, Brian Wong, Joly Sukumaran, Wan Lin Yeo, Steven J. Collier, Scott Novick
  • Method for expression of small RNA molecules within a cell
    Patent number: 9963717
    Abstract: The invention provides methods and compositions for the expression of small RNA molecules within a cell using a lentiviral vector. The methods can be used to express doubles stranded RNA complexes. Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell, which is capable of down regulating the expression of a target gene through RNA interference. A variety of cells can be treated according to the methods of the invention including embryos, embryogenic stem cells, allowing for the generation of transgenic animals or animals constituted partly by the transduced cells that have a specific gene or a group of genes down regulated.
    Type: Grant
    Filed: December 27, 2016
    Date of Patent: May 8, 2018
    Assignee: California Institute of Technology
    Inventors: Carlos Lois-Caballe, David Baltimore, Xiao-Feng Qin
  • Human-mouse chimeric anti-CD147 antibody with non-fucosylated glycosylation
    Patent number: 9963506
    Abstract: The present disclosure relates to a nucleotide sequence comprising the sequence of SEQ ID NO: 5, and/or sequence of SEQ ID NO: 6, vector and host cell line comprising the nucleotide. The present disclosure also relates to an antibody that binds to extracellular region of human CD147, wherein the antibody comprises a heavy chain variable region having the amino acid sequence of SEQ ID NO: 2, and/or a light chain variable region having the amino acid sequence of SEQ ID NO: 1, and the antibody contains a glycoform lacking both fucose residues and xylose residues, pharmaceutical composition comprising the antibody or fragment thereof, the method of producing the antibody or fragment thereof, and use of the pharmaceutical composition in treatment of CD147 expression-related diseases.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: May 8, 2018
    Assignee: FOURTH MILITARY MEDICAL UNIVERSITY
    Inventors: Zhinan Chen, Zheng Zhang, Yang Zhang, Fei Feng, Muren Huhe, Xiangmin Yang
  • Hydrocarbon synthase gene and use thereof
    Patent number: 9957497
    Abstract: A hydrocarbon synthase gene encoding protein having excellent capacity to synthesize a hydrocarbon such as alkane and novel functions is provided. The gene encodes a protein comprising an amino acid sequence comprising a motif sequence shown in SEQ ID NO: 1 and having activity of synthesizing a hydrocarbon with a carbon number one less than that of an aldehyde compound from the aldehyde compound.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: May 1, 2018
    Assignee: TOYOTA JIDOSHA KABUSHIKI KAISHA
    Inventors: Masayoshi Muramatsu, Masakazu Ito
  • Treating cancer with viral nucleic acid
    Patent number: 9957302
    Abstract: This document provides methods and materials related to the use of nucleic acid coding for viruses to reduce the number of viable cancer cells within a mammal. For example, methods for using infectious nucleic acid to treat cancer, engineered viral nucleic acid, methods for making engineered viral nucleic acid, methods for identifying infectious nucleic acid for treating cancer, methods and materials for controlling virus-mediated cell lysis, and methods and materials for assessing the control of virus-mediated cell lysis are provided.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: May 1, 2018
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Stephen James Russell, Elizabeth J. Kelly, Elizabeth M. Hadac
  • Exogenous terminators for controlling fungal gene expression
    Patent number: 9951344
    Abstract: Provided herein are exogenous terminator sequences for use in fungi cell transcriptional termination.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: April 24, 2018
    Assignee: Board of Regents, The University of Texas System
    Inventors: Hal Alper, Kathleen Curran
  • Multi-targeting short interfering RNAs
    Patent number: 9953131
    Abstract: The present invention relates to novel short interfering RNA (siRNA) molecules that are multi-targeted. More specifically, the present invention relates to siRNA molecules that target two or more sequences. In one embodiment, multi-targeting siRNA molecules are designed to incorporate features of siRNA molecules and features of micro-RNA (miRNA) molecules. In another embodiment, multi-targeting siRNA molecules are designed so that each strand is directed to separate targets.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: April 24, 2018
    Assignee: City of Hope
    Inventors: John J. Rossi, Ola Snove, Ali Ehsani, Pal Saetrom, Britta Vallazza, Jane Zhang, Lars Aagaard
  • Adenoviral vector encoding human atonal homolog-1 (HATH1)
    Patent number: 9951351
    Abstract: The invention is directed to a replication-deficient adenoviral vector comprising a nucleic acid sequence encoding a human atonal homolog-1 (Hath1) protein operably linked to a human glial fibrillary acidic protein (GFAP) promoter. The invention also is directed to a composition and method utilizing the adenoviral vector to generate sensory cells in the inner ear of a human.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: April 24, 2018
    Assignee: GenVec, Inc.
    Inventors: Douglas E. Brough, Damodar R. Ettyreddy